Breaking News
January 24, 2019 - Cancer Research UK announces £60 million funding to tackle global cancer challenges
January 24, 2019 - SCHILLER AED FRED easyport helped save life of elderly person in Vienna
January 24, 2019 - Pittcon to highlight UHPLC techniques at 30th James L. Waters symposium
January 24, 2019 - Global task force of bone health experts question effectiveness of spinal fusion procedures
January 24, 2019 - Study demonstrates beneficial effects of influenza vaccination on COPD patients
January 24, 2019 - New findings challenge existing strategies for fighting infectious diseases and germs
January 24, 2019 - Study sheds new light on male infertility
January 24, 2019 - Rebound Therapeutics announces FDA 510k clearance of its AURORA Surgiscope System
January 24, 2019 - 3D printing may aid in the treatment of osteoarthritis
January 24, 2019 - Most gay fathers and their kids face stigma despite legal and social advances, finds study
January 24, 2019 - Melanoma Survival Varies Among U.S. States
January 24, 2019 - Migraine – Genetics Home Reference
January 24, 2019 - Is that really a neglected disease?
January 24, 2019 - Study offers new hope for elimination of malaria
January 24, 2019 - Mice transmit brain benefits of enriched upbringing to non-enriched offspring
January 24, 2019 - Researchers demonstrate strong evidence connecting bacterial pathogen and Alzheimer’s pathogenesisis
January 24, 2019 - Overprescribing of antidepressants may occur more often in elderly patients
January 24, 2019 - FDA authorizes marketing of new test to aid in the diagnosis of M. gen. infections
January 24, 2019 - Health Tip: Simple CPR – MedNews
January 24, 2019 - Diabetes in America, 3rd Edition
January 24, 2019 - Bangladesh ‘Tree Man’ returns to hospital as condition worsens
January 24, 2019 - Costs of gun-related hospitalizations, readmissions examined in study
January 24, 2019 - Good health literacy linked to better adherence to blood pressure medications among Hispanics
January 24, 2019 - Only a minority of patients in the U.S. with type 1 diabetes achieve treatment goals
January 24, 2019 - High fat reduces efficiency of the immune system to fight infectious disease
January 24, 2019 - FDA grants clearance to Hologic’s assay for detection of common sexually transmitted infections
January 24, 2019 - Study highlights need for reliable therapeutic targets for prevention, treatment of cardiovascular diseases
January 24, 2019 - Next step toward replacement therapy in type 1 diabetes
January 24, 2019 - “Scientific serendipity” identifies link between type of RNA and autism
January 24, 2019 - Trump Zeroes In On Surprise Medical Bills In White House Chat With Patients, Experts
January 24, 2019 - Unique form of chronic sinusitis found in older patients
January 24, 2019 - NUS researchers make muscle recovery easier for patients with ingenious medical device
January 24, 2019 - Specific cognitive deficits found in individuals with spinal cord injury
January 24, 2019 - An essential reference for diagnostic ultrasonography and biopsy of the thyroid gland
January 24, 2019 - Proteus Digital Health Launches Digital Oncology Medicines to Improve Patient Outcomes
January 24, 2019 - Study looking to prevent type 1 diabetes follows children into adolescence
January 24, 2019 - Nice doctors make a difference
January 23, 2019 - Blood vessel discovery could advance our knowledge of osteoporosis
January 23, 2019 - New esophageal cancer test uses genetic biomarkers to detect changes in esophagal cells
January 23, 2019 - Study evaluates first-ever Robotic Visualization System for neurosurgery
January 23, 2019 - Scientists reveal new mechanism that could lead to specific treatment of strokes and seizures
January 23, 2019 - Both educational level and occupational orientation predict mother’s smoking during pregnancy
January 23, 2019 - How to (gently) get your child to brush their teeth
January 23, 2019 - Short-term hospital readmissions for gun injuries cost $86 million a year | News Center
January 23, 2019 - New certified reference material for testing residual solvents in cannabis
January 23, 2019 - Gene-edited chickens could prevent future flu pandemic
January 23, 2019 - Cardiovascular disease risk begins even before birth
January 23, 2019 - Younger patients receiving kidney transplant more likely to live longer, shows data
January 23, 2019 - Skin samples hold early signs of prion disease, research suggests
January 23, 2019 - Researchers discover how body initiates repair mechanisms that limits damage to myelin sheath
January 23, 2019 - Fecal transplant from certain donors better than others
January 23, 2019 - Risk for Uninsurance in AMI Patients Reduced With Medicaid Expansion
January 23, 2019 - Readmissions reduction program may be associated with increase in patient-level mortality
January 23, 2019 - Fostering translation and communication in medicine and beyond
January 23, 2019 - To Fight Fatty Liver, Avoid Sugary Foods and Drinks
January 23, 2019 - TPU scientists develop new implants that double the rate of bone lengthening in kids
January 23, 2019 - New sessions at Pittcon 2019
January 23, 2019 - Insilico to present latest findings in AI for Drug Discovery at 3rd Annual SABPA FTD Forum
January 23, 2019 - Opioid overdose patients can be safely discharged an hour after administration of naloxone
January 23, 2019 - Scientists find bacterial extracellular vesicles in human blood
January 23, 2019 - Researchers use modified type of flu virus to develop new therapies for prostate cancer
January 23, 2019 - Researchers gain new insights into development of necrotizing enterocolitis in preemies
January 23, 2019 - Medical expert advises people with epilepsy not to stockpile medicines
January 23, 2019 - CDC study explores link between smoking and clinical outcomes of assisted reproductive technology
January 23, 2019 - Study outlines research priorities for improving pediatric patient care and safety
January 23, 2019 - Bedfont to exhibit NObreath FeNO monitor at Arab Health 2019
January 23, 2019 - Nicotinamide riboside supplementation confers significant physiological benefits to mothers and offspring
January 23, 2019 - Increasing temperatures may help preserve crop nutrition
January 23, 2019 - Many Oncologists in the Dark About LGBTQ Health Needs
January 23, 2019 - Epigenetic change causes fruit fly babies to inherit diet-induced heart disease
January 23, 2019 - Erasing memories could reduce relapse rates among drug addicts
January 23, 2019 - African Americans who smoke cigarettes are more likely to develop peripheral artery disease
January 23, 2019 - Unique data combination helps FinnGen researchers to fund links between genetic factors and health
January 23, 2019 - Parents’ mental health problems associated with reactive attachment disorder in children
January 23, 2019 - Graphene Flagship project studies impact of graphene and related materials on our health
January 23, 2019 - The connection between the Pope and contraceptive pills
January 23, 2019 - Prior dengue infection could protect children from symptomatic Zika
January 23, 2019 - Previous dengue virus infection associated with protection from symptomatic Zika
January 23, 2019 - VISTA checkpoint implicated in pancreatic cancer immunotherapy resistance
January 23, 2019 - The Tiny Camera That Could Revolutionize Cardiovascular Surgery
Developing a High Throughput Mass Spectrometry Platform for Drug Discovery

Developing a High Throughput Mass Spectrometry Platform for Drug Discovery

image_pdfDownload PDFimage_print

Your presentation at Pittcon 2018 focussed on Mass Spectroscopy (MS) based high-throughput screening for drug discovery. What are the current challenges associated with screen samples?

Acoustic mass spectrometry offers us the ability to screen very, very quickly in a very clean way. This is a huge benefit for the high-throughput screening community. As a result, we are able to have a direct measurement of substrate to product conversion, and that’s great because we don’t have to buy extra reagents. We also don’t have to buy labels, which obviously add cost. Higher costs mean we can only screen a reduced number of samples. So, keeping the cost down is important for us too.

In a recent paper co-authored by yourself and Mattias Rohman, you describe the use of RapidFire™ coupled to a triple-quadrupole MS for high-throughput screening. How does this compare to traditional liquid chromatography for electrospray ionization (ESI)?

In the high-throughput screening space, the RapidFire platforms that are now marketed by Agilent are considered to be state of the art for high-throughput screening. It is because they are using a simple solid phase extraction methodology, rather than an LC, that means they can process a sample every eight to ten seconds. However, even at that speed, it’s really not fast enough. Of course, taking away the LC component, to a certain extent also demystifies some of the technology around mass spectrometry and makes it a little bit more user friendly as well.

Can you please tell us about your collaboration with Labcyte and Waters to build a prototype high throughput mass spectrometry platform?

The aim of the collaboration that AstraZeneca has with LabCyte and Waters is really to try and push forwards the boundaries of high-throughput mass spectrometry. Electrospray mass spectrometry is broadly applicable across may areas of drug discovery, and although there are some other high-throughput techniques such as MALDI, many labs will probably have access to electrospray mass spectrometry platforms.

So being able to convert those into a high-throughput technology was really the main aim for this. The use of acoustics is exciting because it gives us an opportunity to use all of the advantages of acoustics, low sample handling and very high-throughput potential, in a way that’s not been used in terms of coupling it to mass spectrometry in the past.

Mass Spec High Throughput Screening from AZoNetwork on Vimeo.

What modification have you made to the acoustic dispenser and what have been the benefits?

Fundamentally, we’ve taken the LabCyte 555 and essentially taken the transducer from inside and brought it outside the instrument, then coupled this to a plate transfer system so that the plate can now move around over the top of this transducer.

The frequency of the transducer has been tuned and the power offset is subtly different from a standard two and a half nanoliter droplet. This enables us to generate a droplet that’s much smaller and therefore more straight forward to ionize. It also gives us better signal in the mass spectrometer itself.

What is the Echo-MS system and what sampling speeds have you been able to obtain?

By coupling the acoustic front end to a standard time of flight or triple quad mass spec, we can achieve throughputs of around three samples per second. When you compare it to the state of the art electrospray system, the RapidFire, which processes samples once every eight to 10 seconds, it gives us a considerable speed advantage. At that sort of throughput, we’re able to process more than 100,000 samples per day and half a million samples per week.

What level of sample screening do you hope to achieve at these levels?

Well so far, within AstraZeneca, we’ve been able to use this technology even though it is still in its prototype stage to support our high-throughput screening campaigns. Last year we ran a full collection screen, 2.2 million samples, and today we’ve probably processed around about 5 million samples through the platform. This is something we’ve never been able to do in the past with a single MS system.

Why is this important to drug discovery in general?

One of the things that it really enables us to do is to build the assays very quickly. We can get a very fast proof of concept using the mass spec to see whether our enzymes can convert substrates into products. Once we’ve established that proof of concept, moving from there to having a proper assay fit for high-throughput screening is a relatively quick process.

Of course, as I said, costs really come down as well without having to invest in additional label it brings the prices down to a much more affordable level. It’s also a very simple process. We simply add the reagents to our plates, and we have the reactions occur, and then the same plate is used to fire samples into the mass detector itself. For example, our last high-throughput screening campaign was probably about 90,000 pounds cheaper than if we had screened using traditional label-based technologies.

What are the next steps in the development of this prototype platform?

We’re still working with prototype systems. I don’t even believe they’re beta products yet, they’re still in the alpha stage. As with any type of research project like this, I think it’s probable that we will get significant improvements in sensitivity, which will really add value as we move much more towards a commercial instrument.

I think we’re still a year to 18 months away from having any kind of commercial offering available, but hopefully we’d like to see it broadly applied in the biochemical screening space. We’re now starting to broaden our view to look at other potential application avenues as well. We’ll be sharing some data here around cell based assays, which would be a first application with the acoustic mass spec in that area as well. We’re very excited about that and hopefully we’ll see more applications in the future.

Why is Pittcon important in helping you share your research?

Pittcon is really important to us because it gives us a really great opportunity to talk to a really broad audience. Pittcon’s renowned for being at the forefront of analytical sciences, and acoustic mass spectrometry is just another analytical tool. Being able to come to a conference such as this one, and be able to talk and access such a wide spectrum of scientific excellence, I think is really important for any project.

About Dr. Jonathan Wingfield

Jonathan joined AstraZeneca in 2000, as part of a team responsible for delivering automation solutions and technology into the disease area teams post HTS.

He was invited to establish a Lead Generation Automation team within Oncology and this evolved into a centralised biochemical screening team in 2006. The centralised team utilized leading edge technology to deliver high quality data to global projects, this included delivery of acoustic droplet ejection technology.

In 2008 the team was awarded the Microsoft Innovation in Pharma award for the innovative development of a LIMS platform. When the Discovery Sciences function was established within AZ, Jonathan moved into a science role supporting biochemical SAR.

He remains interested in landing technologies that can add value to the core drug discovery business, one such example is the acoustic mass spectrometry collaboration between Labcyte and AZ. This project won the SLAS Innovation award (2015) and has generated a significant amount of external interest.

Tagged with:

About author

Related Articles